Compare ADMA Biologics Inc (ADMA) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Under Armour Inc Class A — how do they compare? ADMA Biologics Inc trades at $9.23 (market cap $2.13B), while Under Armour Inc Class A trades at $6.46 (market cap $2.87B). The key difference: Under Armour Inc Class A is the larger of the two by market cap, and Under Armour Inc Class A is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | UAA | |
|---|---|---|
Market Cap | $2.13B | $2.87B |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $8.14 |
52-Week Low | $7.60 | $4.17 |
Enterprise Value | $2.20B | $4.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Under Armour (UAA) trades at $6.74, up 1.66% today, with a bullish technical signal from moving averages but bearish oscillators. Recent earnings show mixed results, with Q4 2026 beating expectations but Q1 2026 missing. The company faces declining revenue and negative net income margins, though international growth and a new Dodge collaboration offer potential catalysts. Cash flow remains negative, and the balance sheet shows rising debt-to-asset ratios, indicating financial strain.
The outlook is cautious due to weak North American sales and margin pressure, but analyst consensus leans hold with a $5.96 price target. Risks include consumer spending softness and execution challenges, while opportunities lie in international expansion and strategic partnerships. Investors should weigh deteriorating fundamentals against potential turnaround efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
